Erste Group Bank Has Negative Opinion of LLY FY2026 Earnings

Eli Lilly and Company (NYSE:LLY) – Analysts at Erste Group Bank dropped their FY2026 EPS estimates for Eli Lilly and Company in a report released on Wednesday, October 21st. Erste Group Bank analyst H. Engel now forecasts that the company will post earnings of $33.87 per share for the year, down from their previous estimate of $36.55. The consensus estimate for Eli Lilly and Company’s current full-year earnings is $33.22 per share.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.40 by $1.98. The business had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The firm’s quarterly revenue was up 47.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS.

A number of other analysts have also commented on LLY. JPMorgan Chase & Co. lifted their price target on Eli Lilly and Company from $1,400.00 to $1,500.00 and gave the stock an “overweight” rating in a report on Monday, September 28th. Truist Financial boosted their price objective on Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Bank of America upped their price objective on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the company a “buy” rating in a research note on Friday, July 10th. Leerink Partners raised their target price on Eli Lilly and Company from $1,309.00 to $1,316.00 and gave the company an “outperform” rating in a research report on Wednesday, October 21st. Finally, Citigroup lifted their target price on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $1,320.25.

Eli Lilly and Company Stock Performance

LLY stock opened at $1,279.29 on Monday. The firm has a market cap of $1.20 trillion, a PE ratio of 40.44, a P/E/G ratio of 1.71 and a beta of 0.46. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. The business has a 50 day moving average of $1,187.35 and a 200-day moving average of $1,086.38. Eli Lilly and Company has a 12-month low of $809.63 and a 12-month high of $1,321.21.

Institutional Trading of Eli Lilly and Company

A number of large investors have recently bought and sold shares of LLY. Ashton Thomas Securities LLC purchased a new stake in Eli Lilly and Company in the third quarter worth $5,003,000. Fishman Jay A Ltd. MI lifted its position in shares of Eli Lilly and Company by 6.0% during the 3rd quarter. Fishman Jay A Ltd. MI now owns 36,210 shares of the company’s stock valued at $41,898,000 after buying an additional 2,034 shares during the last quarter. Black Diamond Financial LLC lifted its position in shares of Eli Lilly and Company by 4.9% during the 3rd quarter. Black Diamond Financial LLC now owns 1,292 shares of the company’s stock valued at $1,495,000 after buying an additional 60 shares during the last quarter. Total Clarity Wealth Management Inc. grew its stake in shares of Eli Lilly and Company by 1.7% during the 3rd quarter. Total Clarity Wealth Management Inc. now owns 2,148 shares of the company’s stock worth $2,485,000 after acquiring an additional 36 shares during the period. Finally, WD Rutherford LLC grew its stake in shares of Eli Lilly and Company by 17.7% during the 3rd quarter. WD Rutherford LLC now owns 4,410 shares of the company’s stock worth $5,103,000 after acquiring an additional 664 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, EVP Patrik Jonsson sold 6,500 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the sale, the executive vice president owned 54,147 shares in the company, valued at $63,628,139.70. This trade represents a 10.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald Zakrowski sold 2,000 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the sale, the chief accounting officer directly owned 1,526 shares in the company, valued at $1,808,325.26. This trade represents a 56.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 13,500 shares of company stock valued at $15,958,170 in the last three months. Company insiders own 0.14% of the company’s stock.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: A U.S. judge declined to block Eli Lilly’s advertising for its weight-loss drugs in a case brought by Novo Nordisk. The ruling supports Lilly’s ability to market its obesity treatments and represents a favorable development in the competitive GLP-1 market. US judge won’t block Eli Lilly ads for weight-loss drugs
• Positive Sentiment: New clinical data for investigational lung-cancer drug olomorasib showed durable first-line activity in KRAS G12C-mutated non-small-cell lung cancer, strengthening Lilly’s pipeline beyond its obesity and diabetes franchises. New data on Lilly’s investigational treatment olomorasib
• Positive Sentiment: Early Phase 1 results for Lilly’s investigational sofe-m plus bevacizumab regimen in ovarian cancer showed high response and disease-control rates without major new safety signals. Although preliminary, the data add potential long-term value to the oncology pipeline. Lilly reports strong Phase 1 ovarian cancer data
• Positive Sentiment: The board declared a quarterly dividend of $1.73 per share, payable December 10 to shareholders of record November 13. The announcement provides a modest signal of financial confidence, though the dividend is not likely to be the primary stock catalyst. Lilly declares fourth-quarter 2026 dividend
• Neutral Sentiment: Analysts have high expectations for the October 29 earnings report, with investors focused on demand for weight-loss drugs, prescription trends, manufacturing capacity and updated full-year guidance. A strong report could extend the rally, while any miss could prompt volatility. Wall Street has high expectations for Eli Lilly
• Negative Sentiment: Competition from Novo Nordisk and broader pricing, patent and market-access pressures remain risks. Analysts also caution that revenue could temporarily soften even as patient numbers grow, while Lilly’s elevated valuation leaves the stock sensitive to weaker-than-expected guidance. Why revenue could dip even as patients grow

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.